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ABSTRACT

THE EFFECT OF PRIMARY AND SECONDARY CIGARETTE SMOKE ON AUDITORY
FUNCTION: A SYSTEMATIC REVIEW
by
HILARY MCMANUS

Advisor: Carol Silverman, Ph.D., M.P.H.
Objective: The goal of this paper was to systematically review literature in order to investigate
the effects of active and passive cigarette smoke on auditory function when assessing outcome
measures including pure tone audiometry, otoacoustic emissions, high-frequency audiometry,
and auditory evoked potentials.
Methods: A comprehensive search using the Medline Complete database was conducted to
identify relevant studies published after 2005. Inclusion criteria included the use of pure tone
audiometry, high-frequency audiometry, otoacoustic emissions, and/or auditory evoked
potentials to examine the effect of primary or secondary cigarette smoke. Studies involving noise
exposure or other confounding factors were excluded.
Results: A total of 19 studies were selected for review based on their research design,
publication date, and inclusion criteria. All included studies achieved a significant negative
correlation between cigarette smoking and auditory function for both active and passive smokers.
Additionally, a dose effect was noted as poorer outcomes were achieved as smoking behavior,
such as packs per year or years smoking, increased.
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Discussion: Significant effects of smoking on auditory function were noted across outcome
measures suggesting a negative effect across levels of the auditory system. Effects on auditory
function were noted even in those who had quit smoking suggesting long term side effects of the
behavior on auditory function. A dose effect was noted with negative effects increasing across
groups from never smokers, to passive smokers, to current smokers. The dose effect was further
stratified within the current smoking group as negative effects increased with an increase in
smoking behavior.
Conclusion: Smoking behavior should be avoided due to its effects on auditory function, as well
as the myriad of other heavily researched deleterious side effects. It would be advantageous to
include the question of smoking behavior in an audiologic evaluation intake form. This question
should also include systematic exposure to secondhand smoke. Additionally, smoking cessation
can be recommended to reduce effects on auditory function.
Key Words: “smoking,” “hearing loss,” “cigarette,” “auditory evoked potentials,” “otoacoustic
emissions,” “audiometry.”
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INTRODUCTION
Worldwide, there are roughly 1 billion (967 million) smokers aged 15 years of age and
older (Ng, Freeman, & Fleming, 2014). Of these 1 billion smokers, 31% are male and 6.1% are
female (Lisowska, Jochem, Gierlotka, Misiotek, & Scierski, 2017). As a result, 88 million adults
and children of at least three years of age are exposed to secondhand smoke (SHS) (Centers for
Disease Control, 2010). By 2025, an estimated 1.5 – 1.9 billion people will be smokers (Shafey,
Dolwick, & Guindon, 2003). According to the Centers for Disease Control (CDC), smoking
prevalence is slightly less than 15% in the United States, with 15.8% of all males and 12.2% of
all females reporting smoking “some days” or “every day.” Of these, 75% report smoking every
day. In terms of age groups, 10.4% of adults age 18 – 24 years, 16.1% of adults age 25 – 44
years, 16.5% of those age 45 – 64 years, and 8.2% of those over 65 years, report current smoking
either “every day” or “some days” (CDC, 2017). Additionally, of those 65 years and older, 80%
have at least one chronic condition, which smoking often exacerbates (Fried, Freedman, Endres,
& Wasik, 1997). Hearing loss itself is ranked third among chronic health conditions in adults age
65 years and older (Collins, 1997). It is a major public health concern with a prevalence of 33%
in adults 65 or more years of age (Davila et al., 2009).
Tobacco use is the leading cause of preventable deaths worldwide (World Health
Organization, 2003). In the United States, cigarette smoking causes 480,000 deaths each year
and increases the risk of death from all causes across genders. Smokers are at a greater risk for a
myriad of health conditions such as bacterial respiratory infections, acute and chronic viral
diseases, oral, laryngeal, esophageal, pancreatic, renal, and bladder cancer, circulatory disease
such as arteriosclerosis, aortic aneurism, stroke, and multiple other organ disorders. Specifically,
smoking increases the risk of coronary heart disease and strokes by 2 – 4 times, of lung cancer in
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men by 25 times, and of lung cancer in women by 25.7 times. Smoking also increases both the
risk and severity of Chronic Obstructive Pulmonary Disease (COPD) with smokers being 12 to
13 times more likely to die from COPD than non-smokers (U.S. Dept. of Health and Human
Services, 2010; 2014). Other smoking effects include reduced fertility, bone health, tooth and
gum health; increased risk of cataracts, age-related macular degeneration, type 2 diabetes,
rheumatoid arthritis; and general adverse effects including inflammation and decreased immune
function (U.S. Department of Health and Human Services, 2001; 2010; 2014). Smokers not only
exhibit poorer vascular and respiratory health, but also present with poorer cognitive health
included an increased risk for dementia, with many showing reduced cognitive performance later
in life (Chang, Ho, Wang, Gentleman, & Ng, 2014; Mons, Schottker, Muller, Kliegal, &
Brenner, 2013).
Cigarette smoking is the primary method of nicotine intake with each cigarette containing
9 – 13 mg of nicotine (Kozlowski, Henningfield, & Brigham, 2001). Nicotine is rapidly absorbed
by nicotinic receptors in the nervous system and can lead to physiologic, cognitive, and sensory
effects (Stratton, Shetty, Wallace, & Bondurant, 2001). Additionally, cigarette smoke contains
more than 4500 complex chemicals including carbon monoxide (CO), carbon dioxide, mercury,
and arsenic (Gopal, Herrington, & Pearce, 2009; Cruickshanks et al., 1998). The effects of such
toxicity are greatly related to number of cigarettes smoked, age of smoking onset, degree of
inhalation, and the different characteristics of cigarette brands such as tar and nicotine content
(Peto, 1986). Smoking simultaneously increases the need for oxygen while decreasing the
amount of oxygen reaching the bloodstream, thus minimizing oxygen available to vital organs
(Moliterno et al., 1994). While it is not yet known how severely these effects impact the auditory
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system, smoking is related to lower blood oxygen levels, increased blood viscosity, vascular
obstruction, and possible ototoxicity (Paschoal & Azevedo, 2009).
Specific to auditory function, the inner ear is dependent on adequate blood supply and
thus may be susceptible to alterations in blood flow caused by tobacco. These alterations include
peripheral vascular changes, such as increased blood viscosity and reduced oxygen availability.
As a result, smoking is known to affect cochlear circulation, inducing vasospasm and
arteriosclerosis in the cochlear blood vessels. Not only does smoking adversely affect cochlear
circulation, but also it adversely affects the cardiovascular system; in turn, this effect on the latter
leads to an increased risk of diabetes, which can result in hearing loss. Nicotine in tobacco smoke
has a direct ototoxic effect on cochlear hair cells. Carbon monoxide in tobacco smoke can cause
a rise in carboxyhaemoglobin levels in smokers, which can reduce the passage of oxygen for the
Organ of Corti. As noted previously, smoking increases the need for oxygen in the human body
and the rise in carboxyhaemoglobin levels results in a reduction of available oxygen. Even
exposure to SHS can damage the inner ear due to hypoxemia or direct injury by nicotine or other
chemicals (Lalwani, Liu, & Weitzman, 2011; Talaat, Metwaly, Khafagy, & Abdelraouf, 2013).
Some researchers have suggested that smokers who are older than 40 years of age have an
increased prevalence of hearing loss, reflecting an additive effect of the normal aging process
and the aforementioned effects of smoking on the cochlea. Age-related degenerative changes can
also affect the vascular structures of the cochlea, just as tobacco does (Chang, Ryou, Jun,
Hwang, Song, & Chae 2016; Ferrite & Santana, 2005).
Nomura, Nakao, and Morimoto (2005) conducted a meta-analysis examining the effect of
smoking on pure-tone thresholds. In contrast with the current review, those investigators
included studies on participants with a history of noise exposure in their meta-analysis. They also
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limited their search to studies utilizing pure-tone average alone as their outcome measure. Their
review revealed a positive association between smoking and pure-tone average. Research
findings reveal significant relative risk for hearing loss from hearing loss in current smokers:
relative risk was 1.33 (95% CI: 1.24, 1.44) based on cross-sectional studies; 1.97 (95% CI: 1.44,
2.70) based on cohort studies; and 2.89 (95% CI: 2.26, 3.70) based on case-control studies.
Furthermore, relative risk also was significant for hearing loss in ex-smokers: relative risk was
1.17 (95% CI: 1.03, 1.33) based on cross-sectional studies; and 1.83 (95% CI: 1.43, 2.35) based
on case-control studies. Although the investigators extracted data on age, noise exposure, and
smoking history, this association was dependent on the adjustment for confounding factors such
as age, noise exposure, and history of ear disorders. The purpose of this study was to conduct a
systematic review of studies on smoking and hearing loss which utilized pure tone thresholds in
the conventional range, ultra high-frequency thresholds, otoacoustic emissions (OAE) and
auditory evoked potentials (AEPs) published since the aforementioned meta-analysis.
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METHODS
The Medline Complete online database was searched. Search filters included peerreviewed journals as well as articles published after 2005. The main search terms utilized were
“smoking,” and “hearing loss.” Supplementary search terms, such as, “cigarettes,” “passive
smoking,” “smoke exposure,” and “auditory evoked potentials” were utilized to find additional
studies for inclusion. This initial search yielded a total of 344 studies. As an existing systematic
review assessed articles prior to 2005, the present review focused on those published in the years
following 2005.
Studies were excluded if they involved concurrent effects of smoking and noise exposure
or if the subjects included infants or children. This resulted in the exclusion of 318 studies.
Subsequently applied exclusion criteria were animal studies or studies on individuals with
schizophrenia and/or major depressive disorder or alcoholism; and studies on middle-ear
pathologies and surgical outcomes resulting in the exclusion of 297 studies. Two studies
originally published in the Georgian Medical news were excluded due to ambiguity of writing
style and reporting of results. These exclusion criteria resulted in the 19 studies evaluated in this
systematic review. Data extracted from the included studies involved conventional and ultra
high-frequency pure-tone thresholds, otoacoustic emissions (OAEs) and AEPs.
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RESULTS
Of the 19 studies evaluated, 89% (17) employed a descriptive, case-control research
design, and 11% (2) employed a descriptive design whereby the characteristics of a single group
of smokers or individuals exposed to secondhand smoke (SHS) are described. The majority of 19
studies (74%) were based on a sample size of at least 30 (Guney, Genc, Kutlu, & Ilhan, 2009;
Gupta, Sood, Atreja, & Agarwal, 2008; Kumar, Gulati, Singhal, Hasan, & Khan, 2013;
Lisowska, Jochem, Gierlotka, Misiotek, & Scierski, 2017; Ohgami Kondo, & Kato, 2011;
Oliveira & Lima, 2009; Paschoal & Azevedo, 2009; Prabhu, Varma, Dutta, Kumar, & Goyal,
2017; Ramkissoon & Chambers, 2008; Ramkissoon & Cole, 2011; Sekher, Sinha, & Jha, 2017;
Sumit et al., 2015), with the remainder (26%) based on a sample size of less than 30 (Gopal,
Herrington, & Pearce, 2009; Negley, Katbamna, Crumpton, & Lawson, 2007). Of the 14 largesample studies, 2 (14%) were population-based. Chang et al. (2016), drew participants from the
Korea National Health and Nutrition Examination Survey (KNHANES). The KNHANES is an
ongoing population study that began in 1998, with individuals who participated from 2010 –
2012 included in the Chang et al. study. Fabry et al. (2011) drew participants from the U.S.
National Health and Nutrition Examination Survey (NHANES) who completed audiometric
testing, provided complete smoking and medical histories, and who had a valid recorded serum
cotinine value.
Of the 19 studies, 15 (79%) compared only 2 groups: smokers versus non-smokers; 1
(5%) involved only current smokers; 1 (5%) included a passive smoking group (those exposed to
SHS) along with groups of smokers and nonsmokers; 1 (6%) involved only a passive smoking
group; and 1 (5%) study compared smokers, non-smokers, and those who had quit smoking in
the past. Of the 19 studies, 17 (90%) studies included non-smokers. Of these 17 studies, 3 (18%)
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included past smokers, or those who quit smoking, in the non-smoking group. Of the 19 studies,
16 (84%) included groups matched for age while the remaining 3 (16%) separated groups into
older and younger participants.
In terms of the quantification of smoke exposure, all studies subjectively assessed smoke
exposure by self-reported responses to either a single question or multiple questions on smoking
status. The questionnaires elicited general health information included in medical records or selfreported basic history involving smoking status, packs/cigarettes per day, frequency of smoking,
and number of years as a smoker. Ohgami et al. (2011) also employed the Brinkman Index (BI)
to examine the frequency or degree of smoking in the participants. The BI represents the number
of cigarettes smoked per day multiplied by the number of years smoking (Brinkman & Coates,
1963). All the individuals in their non-smoking group had a BI of 0, whereas those in the
smoking group all were classified as “light-smokers” with BI scores between 12 and 60. One
study used the Global Initiative for chronic obstructive Lung Disease (GOLD) guidelines to
diagnosis Chronic Obstructive Pulmonary Disease (COPD) (Gupta et al., 2008). The GOLD
guidelines outline the key indicators of a COPD diagnosis, including dyspnea that is progressive
and persistent, chronic cough, chronic sputum production, a history of risk factors, including but
not limited to genetic factors, tobacco smoke, and occupational dusts or vapors, as well as a
family history of COPD and/or childhood factors including low birth weight and childhood
respiratory infections These guidelines also characterize the severity of COPD on a four tier
scale (ABCD) (GOLD, 2019).
Of the 19 total studies, only 5 (26%) additionally used objective measures of smoke
exposure (Fabry et al., 2011; Ramkissoon & Cole, 2011). Gopal et al. (2009) measured breath
carbon monoxide (CO) levels to confirm the current smoking status of study participants. A
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breath CO monitor, used to measure the concentration of CO in the individual’s breath, allows
for the quick and accurate assessment of the presence of CO. Fabry et al. used serum cotinine
levels to determine the level of secondhand smoke exposure. Cotinine, a biomarker of exposure
to tobacco in both active and passive smokers, or those exposed to tobacco smoke, is the primary
metabolite of nicotine (Benowitz, 1996). As the lower limit of detection of serum cotinine is 0.50
ng/mL and the suggested level indicating current smokers is 3 ng/mL or above, only individuals
with levels within this range (0.50 – 3 ng/mL) were included. Ramkissoon and Cole also utilized
cotinine levels to determine smoking status. Additionally, they tested the urine of participants for
the presence of this biomarker, as well as for the presence of nicotine. The self-reports of
smoking status and the biochemical results were in 100% agreement. Mobascher et al. (2009)
utilized carboxyhemoglobin (COHb), a complex of carbon monoxide that forms in red blood
cells when carbon monoxide is inhaled, as an objective measure of smoke exposure
(Thaniyavarn & Eiger, 2014).
Outcome measures included conventional pure-tone thresholds (250 – 8,000 Hz), ultra
high-frequency thresholds, OAEs, and latencies and amplitudes of AEPs. Of the 19 studies, the
majority 14 (74%) assessed conventional pure-tone thresholds; 6 (32%) evaluated extended or
ultra high-frequency pure-tone thresholds; 6 (32%) examined OAEs; and 6 (32%) evaluated the
AEPs. The percentages total more than 100% as some studies evaluated more than one type of
outcome measure. Tables 1 through 4 shows the characteristics of the studies on effects of
smoking on conventional pure-tone thresholds, ultra high-frequency pure-tone thresholds, OAEs,
and the AEPs, respectively.
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Table 1
Characteristics of Studies on Conventional Pure-Tone Thresholds
Study

Size
(N)
12,935

Participants

Fabry et al
(2011)

5147

Gopal et al
(2009)

16

Subject population
aged 20 - 69 yrs who
were not current
smokers but SHS
exposed
Adult male smokers
with no hxc of HL and
hx of smoking of 4 yrs
on average and a mean
use of 17 cigarettes per
day aged 18 – 24

Chang et al
(2016)

South Korean
individuals aged 19+
yrsa: current smoking
group (n= 3,374),
passive smoking group
(n= 2,792), nonsmoking group (n=
6,769)

Inclusion
Exclusion Criteria
Criteria
Smoking group - Presence of unilateral
currently smoke; hearing impairment
passive smoking
group - exposed
to cigarette fumes
daily at home
and/or work; nonsmoking group never smoked and
never exposed to
cigarettes

9
Secondhand
smoke expose serum contine
level at or above
0.050 ng/mL
Current smokers

Current smokers
(based upon Qb and
cotinine levels above 3
ng/mL)
Hearing loss and
outer/middle ear
problems, peripheral
abnormalities ruled
out via otoscopic
examination

Statistical
Analysis
Chi-square (χ2 )
testing, odds ratio
with 95% CI
(adjustments for
age, sex, work
related noise
exposure,
diabetes,
hypertension,
depression, stress,
and regular
exercise) and
linear regression
analysis
Multivariate
logistic regression

Type of
Study
Descriptive
case control

Linear regression
and effect size
(via lmg statistics)

Descriptive
(predictive)

Descriptive

Study
Kumar et al
(2013)

Lisowska et
al (2017)

Size
(N)
148

Participants

84

41 non-smokers (mean
age=33 yrs) and 43
smokers (mean age=35
yrs) aged 25-45. Total
of 46 females and 38
males in Poland.

108 male smokers aged
20 - 60 yrs (mean
age=37 yrs) agematched non-smokers
(mean age=41 yrs)

Inclusion
Criteria
Smokers were
previous or
current smokers

Smoking for 7+
yrs and 15+
cigarettes/day

Exclusion Criteria
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Hx of ototoxic drugs,
diabetes, hypertension,
hearing loss, severe or
frequent ear
infections, ear surgery,
head injury, noise
exposure, family hx of
hearing loss
Hx of audiological
impairment, abnormal
otoscopic
examination, ear
problems, conductive
hearing loss, noise
exposure, ototoxic
drugs, head injury,
family history of
hearing loss; current
disorders of
cholesterol
metabolism, chronic
metabolic disordes,
hypertension, CNSd
disorders, abnormal
BMIe, and other acute
or chronic systemic
conditions

Statistical
Analysis
Unreported

Type of
Study
Descriptive
Case
Control

Shapiro-Wilk test, Descriptive
Student t-test
case control
f
(CEOAE ), MannWhitney-U-test,
Bonferroni
correction (PTTg
and DPOAEh).

Study

Size
(N)
24

Participants

Inclusion
Criteria
12 smokers and 12 non- In smokers: hx of
smokers aged 20-30 yrs 5-8 years of
smoking

Exclusion Criteria

Ohgami et al
(2011)

51

Smoking and nonsmoking males aged 21
- 23 yrs

Light smokers re:
Brinkman Index
(BI) cigarettes/day X
number of yrs
smoked

Oliveira &
Lima (2009)

60

30 male smokers aged
18 -40 yrs (mean
age=31 ± 6 yrs); 30
male age-matched nonsmokers (mean age=28
± 6 yrs)

Smokers were
active smokers
for 5+ yrs

Paschoal &
Azevedo
(2009)

144

72 smokers and 72 nonsmokers paired by
gender and age (20 - 31
yrs)

In smokers:
current smokers
who smoked 5+
cigarettes/day for
1+ yrs

Negley et al
(2007)
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Statistical
Analysis
3 factor ANOVAi

Type of
Study
Descriptive
case control

NA

Mann-Whitney U
test, binary
logistic regression
analysis

Descriptive
case control

Hx of ear disorders,
tinnitus, dizziness,
hearing loss, prior ear
surgery, otoscopic
alterations, workrelated noise exposure,
hypertension, diabetes;
neurologic disease;
PTT > 25 dB HL at
any 1+ frequency;
illiteracy; visual
disorders
Former smokers;
presence of inner or
middle ear disorders,
metabolic disordrs,
hormonal disorders, or

ANOVA

Descriptive
Case
Control

Student t-test,
Mann-Whitney U
test, two ratio
equality tests, and
the Spearman test

Descriptive
case control

Noise exposure or ear
diseases, abnormal
middle-ear pathology
based on
tympanometric screen

Study

Size
(N)

Participants

Inclusion
Criteria

50

25 male smokers and
Current smokers
25 male non-smokers
who have smoked
2
aged 18-40 yrs in India for 1+ yr; PTTs ≤
25 dB HL (.25l 6k Hz)

Ramkissoon
& Cole
(2011)

170

Rogha et al.
(2015)

32

61 males, 109 female;
98 non-smokers and 72
smokers; younger
group n= 80, age 19 30 (mean age 24±3.9)
and older group n=90,
age 45+ mean age
62±9.3); non-smokers
included those who quit
smoking 3+ years prior
Men aged 20 - 60;
smoking group and
non-smoking group
matched for age and
gender

12

Prabhu et al
(2017)

Current smokers self-report
confirmed by
biochemical urine
testing; nonsmokers - never
smoked or quit at
least 3 years prior

Exclusion Criteria

Statistical
Analysis

Type of
Study

ANOVA,
MANOVAj
(UHFk), post-hoc
Sidak Test,
independent t-test,
correlation

Descriptive
case control

Poor overall health,
alcohol or drug
dependency, mental
illness, or neurological
disease

Prevalence,
sensitivity,
specificity,
predictive value
and conditional
probability

Descriptive
Case
Control

No history of ototoxic
drug use, diabetes,
hypertension,
hyperlipidemia,
hypothyroidism, ear
infection/surgeries,
occupational noise
exposure, outer and/or
middle ear disease,
unilateral or
conductive hearing
loss

T-test, ANOVA

Descriptive
case control

noise-induced or druginduced HL
Otological hx of noise
exposure, ototoxic
drugs, diabetes, family
hx of hearing loss;
abnormal middle-ear
function

Study
Sekher et al
(2017)
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Sumit et al
(2015)

Size
(N)
120

Participants

Inclusion
Criteria
60 smokers and 60 non- In smokers:
smokers aged 20-60 yrs currently smoke

184

90 male smokers (mean
age 39 ±12 yrs) and 94
male non-smokers
(mean age 36 ± 12 yrs)
aged 18-60 yrs in
Bagladesh; groups did
not differ on mean age
or BMI

Exclusion Criteria

Chronic supprative
otitis media and other
middle and internal
ear pathology; hx of
ototoxic drugs,
working in a noisy
environment,
congenital anomalies,
and other systemic
diseases such as
diabetes and viral
infection causing
sudden SNHLl or
unilateral SNHL
Hx of alcohol drinking χ2 testing,
habit, use of portable
regression
music player with
analysis
earphone, middle-ear
disease; current illness

Age 18 - 60 yrs

a

g

b

h

Years
Questionnaire
c
History
d
Central nervous system
e
Basal mass index
f
Click evoked otoacoustic emissions

Statistical
Analysis
Descriptive
statistics
(percentages) only

Pure-tone threshold
Distortion product otoacoustic emissions
i
Analysis of variance
j
Multivariate analysis of variance
k
Ultra high frequency
l
Sensorineural hearing loss

Type of
Study
Descriptive
case control

Descriptive
case control

Table 2
Characteristics of Studies on Effects of Smoking on the Ultra High-Frequency Pure-Tone Thresholds
Size
(N)

Participants

Inclusion
Criteria

Exclusion Criteria

Statistical
Analysis

Type of
Study

Lisowska et al
(2017)

84

41 non-smokers (mean
age=33 yrs) and 43
smokers (mean age=35
yrsa) aged 25-45. Total
of 46 females and 38
males in Poland.

Smoking for 7+ yrs
and 15+
cigarettes/day

Shapiro-Wilk test,
Student t-test
(CEOAEe), MannWhitney-U-test,
Bonferroni
correction (PTTf
and DPOAEg).

Descriptive
case control

Negley et al
(2007)

24

12 smokers and 12 nonsmokers aged 20-30 yrs

In smokers: hx of
5-8 yrs of smoking

3 factor ANOVAh,

Descriptive
case control

Ohgami et al
(2011)

51

Smoking and nonsmoking males aged 21 23 yrs

Light smokers re:
Brinkman Index
(BI) cigarettes/day X
number of yrs
smoked

Hxb of audiological
impairment, abnormal
otoscopic examination, ear
problems, conductive
hearing loss, noise
exposure, ototoxic drugs,
head injury, family history
of hearing loss; current
disorders of cholesterol
metabolism, chronic
metabolic disordes,
hypertension, CNSc
disorders, abnormal BMId,
and other acute or chronic
systemic conditions
Noise exposure or ear
diseases, abnormal
middle-ear pathology
based on tympanometric
screening
NA

Mann-Whitney U
test, binary logistic
regression analysis

Descriptive
case control

14

Study

15

Study

Size
(N)

Participants

Inclusion
Criteria

Exclusion Criteria

Statistical
Analysis

Type of
Study

Oliveira &
Lima (2009)

60

30 male smokers aged
18 -40 yrs (mean age=31
± 6 yrs); 30 male agematched non-smokers
(mean age=28 ± 6 yrs)

Smokers were
active smokers for
5+ yrs

ANOVA

Descriptive
Case Control

Paschoal &
Azevedo
(2009)

144

72 smokers and 72 nonsmokers paired by
gender and age (20 - 31
yrs)

In smokers: current
smokers who
smoked 5+
cigarettes/day for
1+ yrs

Student t-test,
Mann-Whitney U
test, two ratio
equality tests, and
the Spearman test

Descriptive
case control

Prabhu et al
(2017)

50

25 male smokers and 25
male non-smokers aged
18-40 yrs in India

Current smokers
who have smoked
for 1+ yr; PTTs ≤
25 dB HL (.25l - 6k
Hz)

Hx of ear disorders,
tinnitus, dizziness, hearing
loss, prior ear surgery,
otoscopic alterations,
work-related noise
exposure, hypertension,
diabetes; neurologic
disease; PTT > 25 dB HL
at any 1+ frequency;
illiteracy; visual disorders
Former smokers; presence
of inner or middle ear
disorders, metabolic
disordrs, hormonal
disorders, or noise-induced
or drug-induced HL
Otological hx of noise
exposure, ototoxic drugs,
diabetes, family hx of
hearing loss; abnormal
middle-ear function

Descriptive
case control

Rogha et al.
(2015)

32

Men aged 20 - 60;
smoking group and nonsmoking group matched
for age and gender

ANOVA,
MANOVAi
(UHFj), post-hoc
Sidak Test,
independent t-test,
correlation
T-test; ANOVA

No hx of ototoxic drug
use, diabetes,
hypertension,
hyperlipidemia,
hypothyroidism, ear
infection/surgeries,
occupational noise
exposure, outer and/or
middle ear disease,
unilateral or conductive
hearing loss

Descriptive
case control

a

Study

Size
(N)

Participants

Inclusion
Criteria

Exclusion Criteria

Statistical
Analysis

Type of
Study

Sumit et al
(2015)

184

90 male smokers (mean
age 39 ±12 yrs) and 94
male non-smokers
(mean age 36 ± 12 yrs)
aged 18-60 yrs in
Bagladesh; groups did
not differ on mean age
or BMI

Age 18 - 60 years

Hx of alcohol drinking
habit, use of portable
music player with
earphone, middle-ear
disease; current illness

χ2 testing,
regression analysis

Descriptive
case control

Years
History
c
Central nervous system
d
Basal mass index
e
Click evoked otoacoustic emissions
f
Pure-tone threshold
g
Distortion product otoacoustic emissions
h
Analysis of variance
i
Multivariate analysis of variance
j
Ultra high frequency
b

16

Table 3
Characteristics of Studies on Effect of Smoking on OAEs
Size
(N)

Participants

Inclusion
Criteria

Exclusion Criteria

Statistical
Analysis

Type of
Study

Gopal et al
(2009)

16

Current smokers

Descriptive
(predictive)

84

Shapiro-Wilk test,
Student t-test
(CEOAEe), MannWhitney-U-test,
Bonferroni
correction (PTTf
and DPOAEg).

Descriptive
case control

Negley et al
(2007)

24

12 smokers and 12 nonsmokers aged 20-30 yrs

In smokers: hx of
5-8 years of
smoking

Hearing loss and
outer/middle ear
problems, peripheral
abnormalities ruled out
via otoscopic
examination
Hx of audiological
impairment, abnormal
otoscopic examination,
ear problems,
conductive hearing loss,
noise exposure, ototoxic
drugs, head injury,
family history of hearing
loss; current disorders of
cholesterol metabolism,
chronic metabolic
disordes, hypertension,
CNSc disorders,
abnormal BMId, and
other acute or chronic
systemic conditions
Noise exposure or ear
diseases, abnormal
middle-ear pathology
based on tympanometric
screening

Linear regression
and effect size (via
lmg statistics)

Lisowska et al
(2017)

Adult male smokers with
no history of HL and hxb
of smoking of 4 yrsa on
average and a mean use
of 17 cigarettes per day
aged 18 - 24
41 non-smokers (mean
age=33 yrs) and 43
smokers (mean age=35
yrs) aged 25-45. Total of
46 females and 38 males
in Poland.

3 factor ANOVAh

Descriptive
case control

17

Study

Smoking for 7+ yrs
and 15+
cigarettes/day

18
a

Study

Size
(N)

Participants

Inclusion
Criteria

Exclusion Criteria

Statistical
Analysis

Type of
Study

Paschoal &
Azevedo
(2009)

144

72 smokers and 72 nonsmokers paired by gender
and age (20 - 31 yrs)

In smokers: current
smokers who
smoked 5+
cigarettes/day for
1+ yrs

Student t-test,
Mann-Whitney U
test, two ratio
equality tests, and
the Spearman test

Descriptive
case control

Prabhu et al
(2017)

50

25 male smokers and 25
male non-smokers aged
18-40 yrs in India

Current smokers
who have smoked
for 1+ yr; PTT ≤ 25
dB HL (.25l - 6k
Hz)

Rogha et al.
(2015)

32

Men aged 20 - 60;
smoking group and nonsmoking group matched
for age and gender

Former smokers;
presence of inner or
middle ear disorders,
metabolic disordrs,
hormonal disorders, or
noise-induced or druginduced HL
Otological hx of noise
exposure, ototoxic
drugs, diabetes, family
hx of hearing loss;
abnormal middle-ear
function
No history of ototoxic
drug use, diabetes,
hypertension,
hyperlipidemia,
hypothyroidism, ear
infection/surgeries,
occupational noise
exposure, outer and/or
middle ear disease,
unilateral or conductive
hearing loss

Years
History
c
Central nervous system
d
Basal mass index
e
Click evoked otoacoustic emissions
f
Pure-tone threshold
g
Distortion product otoacoustic emissions
h
Analysis of variance
i
Multivariate analysis of variance
j
Ultra high frequency
b

ANOVA,
Descriptive
MANOVAi (UHFj), case control
post-hoc Sidak Test,
independent t-test,
correlation
T-test, ANOVA

Descriptive
case control

Table 4
Characteristics of Effects of Smoking on the AEPs
Size
(N)

Participants

Inclusion
Criteria

Exclusion Criteria

Statistical
Analysis

Type of
Study

Gopal et al
(2009)

16

Current smokers

Hearing loss and outer/middle
ear problems, peripheral
abnormalities ruled out via
otoscopic examination

Linear regression
and effect size (via
lmg statistics)

Descriptive
(predictive)

Guney et al
(2009)

64

Adult male smokers with
no history of HL and hxb
of smoking of 4 yrsa on
average and a mean use
of 17 cigarettes per day
aged 18 - 242
32 male and female
smokers and 32 age,
gender and education
level matched healthy
individuals who had
never smoked

Independent
sample t-test and
Pearson's
correlation
coefficient

Descriptive
case
control

Gupta et al
(2008)

80

Independent
sample t-test,
Pearson's
correlation

Descriptive
case
control

19

Study

40 male smokers with
stable COPDi with a
duration of symptoms of
5+ yrs and 40 male agedmatched healthy controls
40+ yrs

Smokers smoked
15+ cigarettes/day
by inhalation for
12+ yrs, all
participants righthanded

Lifetime hx of major medical
disorder (neurological, hepatic,
or cardiovascular); head injury
with loss of consciousness;
seizures; sedative, barbiturate,
alocohol or cocaine abuse or
dependence; uncorrected
auditory or visual impairment;
current psycoactive medication
use; women currently in the
menstration phase of the
menstrual cycle
Smokers: COPD
Smokers: +clinical evidence of
patients with
neurological deficit or
irreversible/partially neuropathy, concomitant
reversible
diabetes, alcoholism, uremia,
obstruction of
cystic fibrosis, sarcoidosis,
airflow, stable
leprosy, malignancy, hereditary
course of disease
disorders involving peripheral
with regular follow nerves; hx of neurotoxic drug
up in the preceding use or traumatic lesion to the
yr, and no
brainstem. Controls: hx of
hospitilizations
smoking or risk factor for
related to COPD in neuropathy.
the prior 6 months

Study

Size
(N)

Jawinski et al
(2016)

Mobascher et
al (2009)

20
Ramkisson &
Chambers
(2008)

a

Inclusion
Criteria

Exclusion Criteria

Statistical
Analysis

1739 Current (n=136), ex(n=272), and never
smokers (n=468) age 40 79 yrs; participants
matched on sex, age,
alcohol and caffeine
consumption, and
socioeconomic status;
non-smokers included
those with no 6 month
history of 5+ cigarettes
per week
1318 German light smokers
(n=325; mean age=36
yrs), heavy smokers
(n=271; mean age=41
yrs), or never smokers
(n=722; mean age=35
yrs) aged 18-65 yrs
(mean age=37 yrs)

Individuals from an
existing study with
sufficient EEGe
assessment; data on
socioeconomic
status, tobacco use,
alcohol and caffeine
consumption, and
hearing threshold
levels

Current psychiatric disorder or
intake of psychotropic
medication; hx of major
neurological disorder, or being
a cigar, cigarillo, stogie, or pipe
smoker; moderate or worse HL
(>55 dB HL)

Repeated measures Descriptive
ANCOVAf with sex case
and age as
control
covariates

Aged 18-65 yrs,
current smoker with
7+ cigarettes per
week/one per day;
paticipant's
grandparents born
in germany; fluent
German speakers

Former smokers, alcohol or
substance abuse in the past 6
months; psychiatric diagnosis
in the past 6 months; nongerman origin; non-fluent in
German; serious impairments
of hearing or vision; pregnany;
CNSg-related medication within
6 months; neurological illness

40

Younger group: age
19-30 yrs; Older
group; age 55-81
yrs. Smokers + on
biochemical urine
analysis; nonsmokers negative
on biochemical
urine analysis

Alcohol or drug dependency,
mental illness, neurological
disease, significant HL, MLRc
contaminated by post-auricular
muscle reflex, mismatched
between urine analysis and self
reported smoking status

ANCOVA with
P300 GFPh as
dependent variable
and smoking status,
gender, and study
site as independent
variable. Age, years
of education,
alcohol use served
as covariates
MANOVAd

Years
History
c
Middle Latency Response
b

Participants

Younger non-smokers
(n=10), younger smokers
(n=10), mean age=25 yrs;
older non-smokers
(n=10) and older smokers
(n=10), mean age= 61
yrs) ; included past
smokers in non-smoking
groups

Type of
Study

Descriptive
case
control

Descriptive
case
control

d

Multivariate analysis of variance
Electroencephalogram
f
Analysis of covariance
g
Central Nervous System
h
Global Field Potential
i
Chronic Obstructive Pulmonary Disease
e
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Pure-Tone Thresholds
Conventional audiometric range
Fourteen of the 19 studies (74%) utilized conventional pure-tone thresholds as an
outcome measure (Chang et al., 2016; Fabry et al., 2011; Gopal et al., 2009; Kumar et al., 2013;
Lisowska et al., 2017; Negley et al., 2007; Ohgami et al., 2011; Oliveira & Lima, 2009; Paschoal
& Azevedo, 2009; Prabhu et al., 2017; Ramikissoon & Cole, 2011; Sekher et al., 2017; Sumit et
al., 2015). Inspection of Table 1 reveals that the studies were performed on current smokers,
individuals who have either never smoked or not smoked in five or more years, as well as
passive smokers, or those who do not actively smoke, but are exposed to smoke in some way.
Table 5 shows the outcome measures, procedures, and findings of the the studies on effects of
smoking on the conventional pure-tone thresholds.
As seen from inspection of Table 5, no statistically significant differences in conventional
pure-tone thresholds between smokers and non-smokers were seen in in 3 of the 14 studies
(21%) (Lisowska et al., 2017; Ohgami et al. 2011; Ramkissoon & Cole, 2011). Ramkissoon and
Cole found no significant difference in conventional pure-tone thresholds between smokers and
non-smokers when examining the presence or absence of mild (PTA > 25 dB dB HL), moderate
(PTA > 40 dB dB HL), severe (PTA > 60 dB HL) hearing loss, or reduced word-recognition
score (WRS < 88%). Ohgami et al. found no significant differences in mean thresholds (1 – 8k
Hz) between smokers and non-smokers. Gopal et al. (2009) found that conventional pure-tone
thresholds (3-frequency PTA at .5, 1, and 2k Hz) did not account for variance in CO levels of
participants. Lisowska et al. found worse pure-tone thresholds in smokers than in non-smokers at
all frequencies tested (.25 – 20k Hz), but these results failed to reach significance. Although no
significant differences among groups occurred on the pure-tone thresholds, Ramkissoon and
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Cole did find that both younger participants, when compared to older participants as well as
smokers compared to non-smokers overestimated their self-reported hearing impairment.
Inspection of Table 5 also reveals that in the remaining 11 of the 14 (79%) studies, the
pure-tone thresholds were significantly poorer in smokers than in non-smokers and passive
smokers. Although the pure-tone thresholds were worse in smokers than in non-smokers and
passive smokers, the thresholds did not always fall outside the normative hearing range (25 dB
HL). In several studies, smokers had significantly poorer mean thresholds across the frequency
range (.25 – 8k Hz) than non-smokers (Kumar et al., 2013; Negley et al, 2015; Oliveira & Lima,
2009; Prabhu et al., 2017). Kumar et al found that the severity of hearing loss (based on the 4frequency PTA across .5, 1, 2, and 4k Hz) increased significantly as the duration of smoking and
number of cigarettes smoked increase. Negley et al., who analyzed the thresholds at .25 to 8k Hz
data using three-factor ANOVAs (subject group x ear side x hearing level), found that the mean
hearing thresholds of smokers were significantly poorer than those for non-smokers, with
maximal effects noted at 6 and 10k Hz. . Oliveira and Lima found significantly higher mean
thresholds at .25 – 6k Hz in smokers (mean = 11.4 dB HL) compared with non-smokers (mean =
9.4 dB HL). Although Prabhu et al. primarily examined the pure-tone thresholds at the ultra high
frequencies, significant differences were noted at 8k Hz with smokers having a poorer mean
threshold than non-smokers. Although exact valus were not reported, based on inspection of the
figures, the mean pure-tone threshold at 8k Hz was estimated to be 26 dB HL for smokers and 12
dB HL for non-smokers. Kumar et al., who examined the 4-frequency PTA (based on .5, 1, 2,
and 4k Hz), found that the prevalence of hearing impairment was higher in smokers (66%) than
non-smokers (15%). Sekher et al. (2017), reported on the prevalence of sensorineural hearing
loss based on pure-tone thresholds, rather than on the degree of hearing loss, in smokers and non-
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smokers. They observed significantly higher prevalence of sensorineural hearing loss in smokers
(48%) than in non-smokers (22%).
Note from Table 5 that in terms of population-based studies, Chang et al. (2016) found
statistically significant differences in the prevalence of hearing loss between smokers and nonsmokers across age groups. They also noted significant differences in speech (5-frequency PTA)
and high frequency PTA (3-frequency). Specifically, smoking prevalence was significantly
related to speech frequency hearing loss (thresholds of ≥ 25 dB HL at .5, 1, 2, 3, 4k Hz) in
participants aged 40 – 69 years, as well as to high frequency-hearing loss (present if thresholds ≥
25 dB HL at 3, 4, and 6k Hz) in participants aged 30-79 years. Current smokers also had a higher
prevalence of hearing loss overall compared to both passive and non-smokers in the 40 – 60 year
age range. After adjusting to age, sex, and noise exposure, the mean speech-frequency PTA was
significantly higher, by 2.5 dB HL (± .33 dB ) in smokers than non-smokers; it was also
significantly higher by 1.6 dB HL (± .33 dB) in smokers than passive smokers Additionally,
passive smokers exhibited a higher prevalence of hearing impairment than non-smokers across
all age groups, although this finding failed to reach significance in any age group. The passive
smoking group exhibited significantly poorer mean speech frequency PTA (2.41 dB HL ± .47
dB) than non-smokers (1.2 dB HL ± .34 dB).
Table 5 further shows that Fabry et al. (2011) found a significant correlation between
SHS exposure and the presence of low-mid frequency hearing loss (PTA > 25 dB HL based on
.5, 1, and 2k Hz) and a significant correlation between former smoking behavior and the
presence of high- frequency hearing loss exceeding 25 dB HL (4-frequency PTA based on 3, 4,
6, 8k Hz).

24
2

Table 5 shows that in one study, although a significant difference in pure-tone threshold
occurred at just a single frequency (8000 Hz) in the left ear between smokers (mean of 4.5 dB
HL) and non-smokers (mean of 3.3 dB HL), significantly more smokers than nonsmokers
presented with tinnitus, and smokers with tinnitus had poorer pure-tone thresholds (.25 – 6k Hz)
than smokers without tinnitus (Paschoal & Azevedo, 2009). Similarly, Rogha et al. (2015) found
poorer mean thresholds at 2000 and 8000 Hz in smokers compared with non-smokers. Based on
inspection of the figures, the estimated mean pure-tone threshold at 2000 Hz was 8 dB HL in
smokers and 3 dB HL in non-smokers; at 8000 Hz, the estimated mean pure-tone threshold was
14 dB HL for smokers and 8 dB HL for non-smokers.
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Table 5
Smoke-Exposure and Outcome Measure, Procedures, and Pure-Tone Threshold Results
Study

Smokers
Defined as
12,935 Qa

Measure of
Description of Outcome
Smoke Exposure Measure
Smoking status
Estimated prevalence of
both speech frequency
hearing impairment
(present if thresholds of
≥25 dB HL at .5, 1, 2, 3,
4k Hz) and high frequency
hearing impairment
(present if thresholds ≥ 25
dB HL at 3, 4, and 6k Hz)
according to smoking
status and stratified by age
group

Procedure

Results

PTTb testing done
in soundproof
booth inside
mobile van using
aura-aural
headphones,
automated
testing.

Fabry et al
(2011)

5147

Q and serum
cotinine
levels

Smoking status

Measured at .5, 1,
2, 3, 4, 6, 8k Hz
(low-mid = .5, 1,
2k Hz; high = 3,
4, 6, 8k Hz)

Smoking related to speech
frequency bilateral HL in age
40 - 69 - Current smoking
group higher prevalance of HL
than passive or non-smoking
group in 40 - 60 age groups
(ORc of 1.39 for smokers); high
frequency HL in age 30 - 79 current smoking group higher
prevalance of HL than passive
or non-smokers (OR of 1.42 for
smokers); Current smokers had
high PTAd thresholds than nonsmokers and passive
smokers***; passive smokers
had higher PTA thresholds than
non-smokers***
Correlation between
secondhand smoke exposure
and low/mid frequency HL**
and for high frequency HL for
former smokers***

Gopal et al
(2009)

16

Q and breath
COe

Breath CO levels

Chang et al
(2016)

N
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Prevalence of low-mid
frequency HL (PTA > 25
dB HL at .5, 1, and 2k Hz)
and high frequency HL
(PTA at 3, 4, 6, 8k Hz >
25 dB HL)
PTT (.25 - 8k Hz), pure
tone average 500, 1000,
and 2000 Hz; ARTf
measured ipsilaterally and
contralaterally; ABRg
latency and amplitude of
wave V; TEOAEh
measured at 1, 1.4, 2, 2.8,

PTT performed
in sound treated
room; AEP
recorded to
rarefaction clicks
at intensity levels
of 40 - 80 dB
nHL

NSi

N

Smokers
Defined as

Measure of
Description of Outcome
Smoke Exposure Measure
and 4k Hz; DPOAEj
measured at 1, 1.4, 2, 2.8,
and 4k Hz; MLRk peak
latency and amplitude of
Na and Pa
Smoking status
Presence of HL defined as
PTA (.5 - 4k Hz) >25 dB
in the worse ear. Severity
classified as mild (>25 and
≤ 40 dB), moderate (>40 ≤
60 dB) and severe (>60
dB)

Kumar et al
(2013)

148

Q

Lisowska et al
(2017)

84

Q

Smoking status

PTT and HFAl mean
thresholds at each
frequency, presence or
absence of CEOAEm,
SOAEn, and DPOAE for
non-smokers vs smokers,
female smokers vs female
non-smokers, male
smokers vs male nonsmokers, female nonsmokers vs male nonsmokers, female smokers
vs. male smokers

Negley et al
(2007)
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Q

Smoking status

PTT - .25-8k Hz; HFA 10-20k Hz; DPOAE - 2-8k
Hz
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Study

Procedure

Results

PTT (.5k-6kHz)

Significantly higher PTT
overall in smoking group*;
severity significantly correlate
with # cigarettes smoked and
duration of smoking*

PTT (.25k-8k Hz; Higher PTT in smokers - NS
HFA (8k-20kHz);
sound treated
room; CEOAE
(present at
response ≥ 3 dB
SPL,
reproducability >
75%), SOAE
(similar to
CEOAE unreported),
DPOAE (SNR >
3 dB)
PTT at 0.25PTT .25 - 8k Hz poorer**
8kHz); HFA at
10-20kHz;
DPOAE at 28kHz).

Study

N

Description of Outcome
Measure
Average thresholds at 1 12k Hz of smoking and
non-smoking group

Results

Ohgami et al
(2011)

PTT (1k-12kHz)

Oliveira &
Lima (2009)

60

Q

Smoking status

Mean thresholds in low
frequency (.25 - 8k Hz)
range and high frequency
(9 - 18k Hz)

PTT .25, .5, 1, 2,
4, 6, 8k Hz; HFA
9, 10, 11.2, 12.5,
14, 16, 18k Hz

PTT poorer at 12k Hz in
smokers*, no differences in
auditory thresholds from 1 8kHz
Significantly higher PTT
overall (RE & LE) in smokers
and non-smokers****,

Paschoal &
Azevedo
(2009)

144

Q

Smoking status

Occurrence of tinnitus,
PTT at .25 - 8k Hz, HFA
at 10000, 12500, 14000,
and 16000 Hz, TEOAE
response, and presence of
TEOAEo suppression

PTT(.25-8kHz)
and HFA (1016kHz) measured
in sound-proof
booth

Prabhu et al
(2017)

50

Q

Smoking status

HFA thresholds at 8, 9,
10.225, 12.5, and 16k Hz.
DPOAE amplitude at 8, 9,
10.25, 12.5, 14, and 16k
Hz

HFA conducted
using HAD-200
headphones.
DPOAEs
conducted in
sound-treated
room

Ramkissoon
& Cole (2011)

170

Subject
report and
urine test for
prescence/ab
sence of
nicotine and
cotinine

Smoking status

Presence or absence of
mild (PTA > 25 dB),
moderate (PTA > 40 dB),
severe (PTA > 60 dB) and
speech (WRSp < 88%)
impairment

Self reported
hearing
impairment, PTT
.25, .5, 1, 2, 4, 6,
8k Hz, speech
reception
threshold, word
recognition

28

Measure of
Smoke Exposure
Smoking status re
BI

Procedure

51

Smokers
Defined as
Q

Worse thresholds for those
with tinnitus, than those
without***, worse PTT
between .25 - 6K Hz in
smokersNS, and 8000Hz left
ear* (median of 5 in smokers
and 2.5 in non-smokers)
Poorer PTT smokers**.

NS

Study

N
32

Smokers
Defined as
Q

Measure of
Description of Outcome
Smoke Exposure Measure
Smoking status
Mean thresholds at .25 16k Hz; Abnormal results
for DPOAE/TEOAE
considered <6 at 1 000,
2000, 4000, and 6000 Hz

Rogha et al.
(2015)

Sekher et al
(2017)

120

Q

Smoking status

Sumit et al
(2015)

184

Q

Smoking status

Presence or absence of
mild, moderate, or severe
SNHLq
Presence of low/mid
frequency HL if PTA of 1
and 4k Hz exceeded 20
dB, and high frequency
HL if PTA at 8 and 12k
Hz exceeded 40 dB

Procedure

Results

Pure tone testing
using AC 40
clinical
audiometer; OAE
performed using
Eclipse EP25
device

Higher thresholds at 2000 and
8000 Hz in smokers compared
to non-smokers ***

Prevalence of SNHL higher in
smokers
PTT (1k 4k, 8k,
12kHz) measured
in soundproof
booth using iPod
with headphones

29
a

l

b

m

Questionnaire
Pure Tone Threshold
c
Odd’s Ratio
d
Pure Tone Average
e
Carbon Monoxide
f
Acoustic Reflex Threshold
g
Auditory Brainstem Response
h
Transient Evoked Otoacoustic Emissions
i
Non-significant
j
Distortion Product Otoacoustic Emissions
k
Middle Latency Responses

High Frequency Audiometry
Click Evoked Otoacoustic Emissions
n
Spontaneous Otoacoustic Emissions
o
Transient Evoked Otoacoustics Emissions
p
Word Recognition Score
q
Sensorineural hearing loss

*p <0.05
**p <0.01
***p <0.00

Smoking related to
significantly worse PTT at 8
and 12k Hz*; PTT signficantly
worse in those who smoked >5
years than those who smoked 1
- 5 years at 12k Hz***;
Prevalence of HL was higher in
smokers of both age groups*;
Controlling for age and BMI,
smoking increases liklihood of
HL 4.9, 4.74, 5.04, and 2.85
times for 12, 8, 4, and 1k Hz,
respectively***

Extended high-frequency pure-tone thresholds
Extended high-frequency pure-tone thresholds (i.e., at frequencies above 8000 Hz) were
assessed as an outcome measure in 8 of the 19 studies, (42%) (Lisowska et al., 2017; Negley et
al., 2007; Ohgami et al., 2011; Oliveira & Lima, 2009; Paschoal & Azevedo, 2009; Prabhu et al.,
2017; Rogha et al., 2015; Sumit et al., 2015). Table 6 shows the outcome measures, procedures,
and findings of the studies on effects of smoking on the extended high-frequency pure-tone
thresholds. In 2 of these 8 studies (25%), however, the only extended high-frequencies examined
were 10 – 12kHz, and these frequencies were included within the conventional audiometric
frequency range (Ohgami et al.; Sumit et al). Although no significant differences between
smokers and non-smokers were found in 2 studies (Negley et al.; Rogha et al.), significant
differences in extended high-frequency thresholds between smokers and non-smokers were
obtained in the remaining 4 (80%) of the studies assessing ultra high frequencies separate from
the conventional pure tone range. In three of these studies, significantly worse thresholds at all
frequencies (10 – 16k Hz) were obtained in smokers compared with non-smokers (Lisowska et
al.; Oliveira & Lima; Prabhu et al.). Paschoal and Azevedo, on the other hand, found
significantly worse high-frequency thresholds in smokers than in nonsmokers at only 12,000 and
14,000 Hz; at 12k Hz. They reported that the mean threshold was 31 dB HL in smokers versus
21 dB HL in non-smokers; at 14k Hz, the mean threshold was 38 dB HL in smokers versus 28
dB HL in non-smokers.
Inspection of Table 6 shows that Sumit et al. (2015), examining only 10 – 12k Hz in
terms of extended high-frequency pure-tone thresholds, reported that current smokers with a
history of smoking for more than 5 years had significantly worse pure-tone thresholds at 12k Hz
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than current smokers with a history of smoking for only 1 – 5 years. This finding is suggestive of
a dose effect, or an increase in hearing thresholds with increases in years of smoking. Ohgami et
al. (2011) found poorer mean pure-tone thresholds at all frequencies across the frequency range
from .25 to 12k Hz in smokers compared to non-smokers. Significant differences, however, in
mean pure-tone threshold between smokers (estimated mean of 37 dB SPL, based on inspection
of the figure) and non-smokers (estimated mean of 29 dB SPL, based on inspection of the figure)
occurred only at 12k Hz.
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Table 6
Smoke-Exposure and Outcome Measure, Procedures, and Ultra High-Frequency Pure-Tone Threshold Results
Study

N

Description of Outcome
Measure

Procedure

Results

Lisowska et al
(2017)

PTTb, HFAl,
CEOAEm,
SOAEn,
DPOAEj

24

Q

Smoking status

Ohgami et al
(2011)

51

Q

Smoking status
re: BIs

PTT & HFA
(subject group x
ear side x
hearing level as
a function of test
frequency),
DPOAE (subject
group x ear side
x test frequency
as a function of
SNRr and
absolute
amplitudes)
PTT

PTT (.25k-8k Hz;
HFA (8k20kHz); sound
treated room;
CEOAE (present
at response ≥ 3
dB SPL,
reproducability >
75%), SOAE
(similar to COAE
- unreported),
DPOAE (SNR >
3 dB)
PTT at 0.258kHz); HFA at
10-20kHz;
DPOAE at 28kHz).

Higher high
frequency PTT in
smokersNS

Negley et al
(2007)

PTT and HFA mean
thresholds at each
frequency, presence or
absence of COAE,
SOAE, and DPOAE for
non-smokers vs smokers,
female smokers vs female
non-smokers, male
smokers vs male nonsmokers, female nonsmokers vs male nonsmokers, female smokers
vs. male smokers
PTT - .25-8k Hz; HFA 10-20k Hz; DPOAE - 28k Hz

Average thresholds at 1 12k Hz of smoking and
non-smoking group

PTT (1k-12kHz)

PTT poorer at 12k
Hz in smokers*, no
differences in
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Measure of
Smoke
Exposure
Smoking status

Outcome
Measures

84

Smokers
Defined
as
Qa

NSi

Study

N

Smokers
Defined
as

Measure of
Smoke
Exposure

Outcome
Measures

Description of Outcome
Measure

Procedure

Results

auditory thresholds
from 1 - 8kHz
Significantly higher
PTT overall (RE &
LE) in smokers and
non-smokers****,

33

Oliveira &
Lima (2009)

60

Q

Smoking status

PTT, HFA

Mean thresholds in low
frequency (.25 - 8k Hz)
range and high frequency
(9 - 18k Hz)

PTT .25, .5, 1, 2,
4, 6, 8k Hz; HFA
9, 10, 11.2, 12.5,
14, 16, 18k Hz

Paschoal &
Azevedo
(2009)

144

Q

Smoking status

PTT, HFA,
TEOAEo

Occurrence of tinnitus,
PTT at .25 - 8k Hz, HFA
at 10000, 12500, 14000,
and 16000 Hz, TEOAE
response, and presence of
TEOAE suppression

PTT(.25-8kHz)
and HFA (1016kHz) measured
in sound-proof
booth

Prabhu et al
(2017)

50

Q

Smoking status

PTT, HFA,
DPOAE

HFA thresholds at 8, 9,
10.225, 12.5, and 16k Hz.
DPOAE amplitude at 8,
9, 10.25, 12.5, 14, and
16k Hz

HFA conducted
using HAD-200
headphones.
DPOAEs
conducted in
sound-treated
room

Rogha et al.
(2015)

32

Q

Smoking status

PTT, DPOAE,
TEOAE, HFA

Mean thresholds at .25 16k Hz; Abnormal
results for
DPOAE/TEOAE
considered <6 at 1 000,
2000, 4000, and 6000 Hz

Pure tone testing
using AC 40
clinical
audiometer; OAE
performed using
Eclipse EP25
device

Worse high
frequency PTT at
12000 and 14000
Hz in smokers
(median of 20 in
non-smokers and
30 in smokers)***
Poorer HFA for
smokers**.
Positive correlation
between HFPTT
and number of
years smoking*,
number of
cigarettes smoked
per day*, and
frequency of
smoking*
NS

Study

N

Sumit et al
(2015)

184

Smokers
Defined
as
Q

Measure of
Smoke
Exposure
Smoking status

Description of Outcome
Measure

Procedure

Results

PTT

Presence of low/mid
frequency HL if PTA of 1
and 4k Hz exceeded 20
dB, and high frequency
HL if PTA at 8 and 12k
Hz exceeded 40 dB

PTT (1k 4k, 8k,
12kHz) measured
in soundproof
booth using iPod
with headphones

Smoking related to
significantly worse
PTT 12k Hz*; PTT
signficantly worse
in those who
smoked >5 years
than those who
smoked 1 - 5 years
at 12k Hz***;
Controlling for age
and BMI, smoking
increases liklihood
of HL 4.9, 4.74,
5.04, and 2.85
times for 12, 8, 4,
and 1k Hz,
respectively***
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Outcome
Measures

a

r

b

s

Questionnaire
Pure Tone Threshold
c
Odd’s Ratio
d
Pure Tone Average
e
Carbon Monoxide
f
Acoustic Reflex Threshold
g
Auditory Brainstem Response
h
Transient Evoked Otoacoustic Emissions
i
Non-significant
j
Distortion Product Otoacoustic Emissions
k
Middle Latency Responses
l
High Frequency Audiometry
m
Click Evoked Otoacoustic Emissions
n
Spontaneous Otoacoustic Emissions
o
Transient Evoked Otoacoustics Emissions
p
Word Recognition Score
q
Sensorineural hearing loss

Signal to noise ratio
Brinkman Index

*p <0.05
**p <0.01
***p <0.001

Otoacoustic Emissions
Six of the 19 (32%) studies utilized OAEs, such as transient evoked otoacoustic
emissions (TEOAEs), distortion product otoacoustic emissions (DPOAEs), click-evoked
otoacoustic emissions (CEOAEs), and spontaneous otoacoustic emissions (SOAEs), as an
outcome measure (Gopal et al., 2009; Lisowska et al., 2017; Negley et al., 2007; Paschoal &
Lima, 2009; Prabhu et al., 2017; Rogha et al., 2015). Table 7 shows the outcome measures,
procedures, and findings of the the studies on effects of smoking on OAEs. As seen from Table
7, all studies employed a questionnaire as an indicator of smoke exposure. Only one study
involved an objective indicator of smoke exposure; in that study the objective indicator was
breath CO levels (Gopal et al.).
Inspection of Table 7 reveals that Prabhu et al. (2017) as well as Negley et al. (2007)
obtained significantly lower mean DPOAE amplitude levels in smokers than in non-smokers at 8
– 16k Hz and at 2 – 8k Hz, respectively. Negley et al. observed this finding at both high (70 dB
SPL) and moderate (65 and 50 dB SPL) intensities. Lisowska et al. (2017) also found
significantly lower DPOAE amplitudes in smokers than in nonsmokers, but only at f2 = 1685 Hz
in males. They also observed that the input/output function of DPOAE differed between male
smokers and male non-smokers as well as male smokers and female smokers, but this result was
not statistically significant. Gopal et al. (2009) found that DPOAE amplitude was a significant
predictor of measured CO levels. Specifically, the DPOAE for the left ear decreased with
increases in CO levels. Rogha et al. (2015) showed a decrease in DPOAE amplitude at 1000,
2000, 4000, and 6000 Hz in smokers compared with non-smokers, but found no significant
differences in TEOAE amplitudes between groups.
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Further review of Table 7 shows that not only did the overall occurrence of TEOAE
responses as well as presence per frequency band at 3000 – 4000 Hz differ significantly between
smokers and non-smokers, but also the incidence of absent TEOAEs was higher in smokers then
in non-smokers (Paschoal & Azevedo, 2009). Also, Lisowska et al. (2017) observed significantly
lower levels of CEOAEs in male smokers compared with those in male non-smokers and in
female smokers. But the difference in rates of present SOAEs between were male smokers and
male non-smokers as well as between male and female smokers failed to reach significance.
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Table 7
Smoke-Exposure and Outcome Measure, Procedures, and OAE Results

37

Study

N

Smokers
Defined as
Qa and
breath COb

Measure of
Smoke Exposure
Breath CO levels

Gopal et al (2009)

16

Lisowska et al
(2017)

84

Q

Smoking status

Negley et al
(2007)

24

Q

Smoking status

Description of Outcome
Measure
PTTc (.25 - 8k Hz), pure
tone average 500, 1000, and
2000 Hz; ARTd measured
ipsilaterally and
contralaterally; ABRe
latency and amplitude of
wave V; TEOAEf measured
at 1, 1.4, 2, 2.8, and 4k Hz;
DPOAEg measured at 1, 1.4,
2, 2.8, and 4k Hz; MLRh
peak latency and amplitude
of Na and Pa
PTT and HFAj mean
thresholds at each frequency,
presence or absence of
CEOAEk, SOAEl, and
DPOAEm for non-smokers
vs smokers, female smokers
vs female non-smokers,
male smokers vs male nonsmokers, female nonsmokers vs male nonsmokers, female smokers vs.
male smokers

Procedure

Results

PTT performed in
sound treated room;
AEPi recorded to
rarefaction clicks at
intensity levels of
40 - 80 dB nHL

Right and left ear
DPOAE**** variance
accounted for in CO
levels

PTT (.25k-8k Hz;
HFA (8k-20kHz);
sound treated room;
CEOAE (present at
response ≥ 3 dB
SPL,
reproducability >
75%), SOAE
(similar to CEOAE
- unreported),
DPOAE (SNR > 3
dB)

PTT - .25-8k Hz; HFA - 1020k Hz; DPOAE - 2-8k Hz

PTT at 0.25-8kHz);
HFA at 10-20kHz;

Overall CEOAE levels
lower in male smokers
compared to male nonsmokers and female
smokers*, lower levels of
DPOAE at f2=1685 Hz in
male smokers*, I/O
function of DPOAE
differed between male
smokers and male nonsmokers/female smokersNSo, lower rates of SOAE
in male smokers
compared with male nonsmokers/female smokers
- NS
Lower DPOAE
amplitudes in smokers at
high (70 dB SPL)* and

Study

N

Smokers
Defined as

Measure of
Smoke Exposure

Description of Outcome
Measure

Procedure

DPOAE at 28kHz).
Occurrence of tinnitus, PTT PTT(.25-8kHz) and
at .25 - 8k Hz, HFA at
HFA (10-16kHz)
10000, 12500, 14000, and
measured in sound16000 Hz, TEOAE response, proof booth
and presence of TEOAE
suppression
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Paschoal &
Azevedo (2009)

144

Q

Smoking status

Prabhu et al
(2017)

50

Q

Smoking status

HFA thresholds at 8, 9,
10.25, 12.5, and 16k Hz.
DPOAE amplitude at 8, 9,
10.25, 12.5, 14, and 16k Hz

Rogha et al.
(2015)

32

Q

Smoking status

Mean thresholds at .25 - 16k
Hz; Abnormal results for
DPOAE/TEOAE considered
<6 at 1 000, 2000, 4000, and
6000 Hz

HFA conducted
using HAD-200
headphones.
DPOAEs
conducted in
sound-treated room
Pure tone testing
using AC 40
clinical audiometer;
OAE performed
using Eclipse EP25
device

a

g

m

b

h

n

Questionnaire
Carbon Monoxide
c
Pure Tone Threshold
d
Acoustic Reflex Threshold
e
Auditory Brainstem Response
f
Transient Evoked Otoacoustic Emissions

Distortion Product Otoacoustic Emissions
Middle Latency Response
i
Auditory Evoked Potentials
j
High Frequency Audiometry
k
Click Evoked Otoacoustic Emissions
l
Spontaneous Otoacoustic Emissions

Results
moderate (65 and 50 dB
SPL)** intensity levels
Overall TEOAE
responses as well as
responses at 3000 - 4000
Hz in both ears sig.
different in smokers**;
higher incidence of
absent TEOAE with
normal hearing in
smokers*; TEOAE
suppression was also
significantly different in
both ears (medians of 3.2
smokers, 2.5 nonsmokers)***
Reduction in DPOAE
amplitude, including
HFOAEn*

Decreased in DPOAE
amplitude at 1000, 2000,
4000, and 6000 Hz in
smokers compared to
non-smokers ***

Distortion Product Otoacoustic Emissions
High Frequency Otoacoustic Emissions
o
Non-significant
*p <0.05
**p <0.01
***p <0.001

Auditory Evoked Potentials
Smoking effects on AEPs were examined in 6 (32%) of the 19 studies. Table 8 shows the
outcome measures, procedures, and findings of the the studies on effects of smoking on AEPs.
As seen from inspection of Table 8, significant, adverse effects of smoking on the AEPs
occurred in all included studies (Gopal et al., 2009; Guney et al., 2009; Gupta et al., 2008;
Jawinski et al., 2016; Mosbacher et al., 2009; Ramkissoon & Chambers, 2008;). Gopal et al.
(2009), who examined the auditory brainstem responses (ABR), found that the ABR peak wave
V amplitude at 80 dB nHL in both ears accounted for variance in CO levels. The negative
correlation between wave V amplitude and CO level was seen only in the left ear. For the left
ear, Gupta et al. (2008) found significantly prolonged mean latencies for I, III, and V and
significantly prolonged III-V and I-V interpeak latencies in smokers with COPD as compared
with healthy non-smokers. Similar findings were obtained for the right ear, except that no
significant difference between groups was obtained for the mean wave I peak latency; the mean
peak latency for wave IV was significantly prolonged for wave IV in the group of smokers with
COPD as compared with the control group; and the I-III interpeak latency also was significantly
prolonged in the smokers with COPD as compared with the control group. In both ears, the peak
amplitudes for waves I and V in the smokers with COPD were significantly reduced as compared
with those for the control group. Additionally, in the left ear, the peak latency for waves I and III
significantly correlated negatively with Forced Expiratory Volume (FEV) (r = -.37 and r = -.33,
respectively) and the peak amplitude of wave I significantly correlated negatively with smoking
packs years (r = -.34). In the right ear, the peak amplitude of wave I correlated positively with
the duration of COPD illness (r = .38); the investigators did not speculate on a possible
explanation of this finding. Of the COPD patients 65% presented with various ABR
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abnormalities. Specifically, 60% presented with increased latencies of waves I – V and increased
interpeak latencies of I – III, I – V, and III – V. A decrease in the amplitude of wave V – Va
presented in 17.5% of patients and a decrease in wave I – Ia amplitude was noted in 12.5% of
patients.
As seen in Table 4, Ramkissoon and Chambers (2008) compared auditory middle latency
responses (MLRs) in non-smokers as well as smokers in the “chronic” condition and the “acute”
condition. Inspection of Table 8 reveals that they employed an objective measure of smoking
status. Additionally, they controlled for age by having age be a factor with two levels (older vs.
younger adults) in the MANOVA. Initially, for the chronic condition, smokers were tested at the
point in the day in which they had smoked half their total daily consumption of cigarettes but had
abstained from smoking two hours prior to testing. Smokers were then tested again immediately
after smoking a cigarette of their usual brand; this represented the acute condition. The results of
MANOVA revealed the absence of a significant effect on Na-Pa amplitude when chronic
smokers were compared with non-smokers; additionally, the interaction of age and smoking was
nonsignificant. For the acute condition, the MANOVA results also revealed significantly larger
Na-Pa amplitudes in the acute than in the chronic condition, in both age groups. The authors
speculated that this finding possibly reflected an excitatory effect of nicotine that is similar to the
excitatory effect of acetylcholine in the subcortical regions of the primary auditory pathway
(inferior colliculus and thalamus to the cortex) and in the secondary auditory pathways
(projections from the reticular formation to the thalamus and cortex). These regions serve as
generator sites for Na and Pa.
As seen in Tables 4 and 8, Jawinkski et al. (2016) investigated N1-P2 amplitudes in those
who had never smoked, ex-smokers, and current smokers. Significant differences were achieved
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between ex-smokers and never smokers as well as current and never smokers, but not between
ex- and current smokers. Individuals who had never smoked exhibited the highest N1-P2
amplitudes followed by ex-smokers and finally current smokers. The steepest increase of N1-P2
amplitudes across increasing presentation levels was found in those who had never smoked,
followed by ex-smokers, and then by current smokers who demonstrated the shallowest increase.
Packs per day and pack years was associated with reduced N1-P2 amplitudes at 72, 78, 84, and
90 dB SPL in ex- smokers.
Inspection of Table 8 further shows that two studies utilized the long-latency P300 to
compare smokers with non-smokers (Guney et al., 2009; Mosbacher et al., 2009). Mobascher et
al. found that those who never smoked had a higher P300 global field potential (GFP) than light
smokers. Additionally, those who never smoked and light smokers had higher P300 GFPs than
heavy smokers. The P300 current source density (CSD) was also reduced in smokers compared
with those who never smoked, with heavy smokers having the lowest P300 CSD. In that study,
the Fagerstrom test for nicotine dependence (FTND) was employed as the scale to represent an
individual’s physical dependence on nicotine (Heatherton et al., 199991). Following age, the
FTND was the second best predictive of P300 GFP. Guney et al. reported that at Fz, the P300
and N1 amplitudes were reduced, and N1 latency was prolonged in smokers as compared with
non-smokers. At Cz, N1 amplitude was also lower in smokers than in non-smokers.
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Table 8
Smoke-Exposure and Outcome Measure, Procedures, and AEP Results
N

Smokers
Defined as

Gopal et al
(2009)

16

Qa and breath
COb

Guney et al
(2009)

64

Q

Measure of
Smoke
Exposure
Breath CO
levels

42

Study

Smoking
status

Description of
Outcome
Measure
PTTc (.25 - 8k
Hz), pure tone
average 500,
1000, and 2000
Hz; ARTd
measured
ipsilaterally and
contralaterally;
ABRe latency and
amplitude of
wave V; TEOAEf
measured at 1,
1.4, 2, 2.8, and 4k
Hz; DPOAEg
measured at 1,
1.4, 2, 2.8, and 4k
Hz; MLRh peak
latency and
amplitude of Na
and Pa
N1 latency and
amplitude, P2
latency and
amplitude, P300
latency and
amplitude

Procedure

Results

PTT performed in sound treated
room; AEPi recorded to
rarefaction clicks at intensity
levels of 40 - 80 dB nHL

Right**** and left ear ABR
peak V amplitude at 80
dBnHL**, right ear ABR peak V
amplitude at 40 dBnHL****
were significant predictors of
CO levels; these 5 predictors
accounted for 75% of the
variance in CO levels

ERPj recordings in quiet room;
oddball paradigm -2kHz target
tone presented 20% of the time,
1kHz non-target presented 80%
of the time at 80 dB. Peak
latencies measured at Cz and Fz

P300 amplitude at Fz was lower
in smokers than nonsmokers***; N1 amplitude at Fz
was lower in smokers than in
non-smokers**; N1 amplitude at
Cz was lower in smokers than
nonsmokers*; N1 latency at Fz
was prolonged in smokers
compared to nonsmokers*

N

Smokers
Defined as

Gupta et al
(2008)

80

Q and
GOLDk
guidelines

Jawinski et
al (2016)

1739 Q

Measure of
Smoke
Exposure
Presence or
absence of
COPDl,
spirometry

Description of
Outcome
Measure
Latencies of
wave I, II, III, IV,
and V, interpeak
latencies of I-III,
I-V, and III-V,
amplitude of
waves I and V

Procedure

Results

AEP recordings performed in
sound-proof room with a click
stimulus of 70 dB nHL at rate of
11.1/s

Smoking
status

N1 - P2
amplitude at 72,
78, 84, 90, and 96
dB SPL as well
as mean
intensities, the
linear slope, and
the median slope

N1-P2 amplitude at various
intensities (linear and median
slopes across intensities) in sound
attenuated booth with insert
earphones 450 pseudorandomized 1k Hz tones (30 ms
duration, 10 ms rise/fall times) at
5 calibrated intensities (72, 78,
84, 90, 96 dB SPL)

In both ears, COPD patients,
prolonged wave I***; interpeak
latencies of III-V and I-V
prolonged in COPD patients vs.
controls**; Amplitude of wave I
and V were reduced in COPD
patients***;
LE: latencies of waves I, III, and
V prolonged in COPD patients
vs. controls***; latencies of
waves II and IV also prolonged
but were NS; wave III***
correlated negatively with FEVm;
Amplitude of wave I correlated
negatively with packs per years
smoking*
RE: latencies of waves III, IV,
and V prolonged in COPD
patients vs. controls***;
interpeak latency of I-III were
prolonged in the COPD
group***; Amplitude of wave I
correlated negatively with
duration of illness**
Never smokers exhibited highest
N1-P2 amplitudes followed by
ex-smokers and current
smokers**; Significant
difference between ex- and never
smokers*, current and never
smokers*, but not between exand current smokers; Steepest
increase of N1-P2 amplitudes of
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Study

Study

Mobascher
et al (2009)

N

Smokers
Defined as

Measure of
Smoke
Exposure

44

1318 Q, COHbn
Age,
measurement, smoking
FTNDo
status, and
gender

Description of
Outcome
Measure

P300 amplitude

Procedure

P300: oddball paradigm, 2kHz
tone (target tone) presented 20%
of the time, 1.5kHz tone (nontarget tone) presented 80% of the
time. Right-hand button press to
target tone

Results

never smokers, ex- with
intermediate phenotype, and
current smokers showing
shallowest increase*; Never
smokers steeper increase in N1P2 amplitudes than ex-**; Packs
per day and pack years
associated with reduced N1-P2
amplitudes at 72,78,84, and 90
dB SPL in ex- smokers*; NSp
dose effect for current smokers
NS effect of smoking status on
P300 latency or reaction time.;
Never smokers had higher P300
GFPq than light smokers**;
Never smokers and light
smokers had higher P300 GFP
than heavy smokers***; P300
CSDr reduced in smokers
compared to never smokers with
heavy smokers having the lowest
P300/P3b CSD; FTND was the
second most predictive regressor
of P300 GFP*** following
age***

Study

N

Smokers
Defined as

Ramkisson
&
Chambers
(2008)

40

Q and urine
analysis

Measure of
Smoke
Exposure
Age and
smoking
status

Description of
Outcome
Measure
Absolute latency
of waves V, Pa,
and Na, and
relative
amplitude of
waves V-Na and
Na-Pa on MLR

Procedure

Results

Rarefaction click stimuli
presented at 70 dBnHL. Testing
was performed on smokers after
they had smoked half of their
daily cigarette consumption, but
were asked to abstain two hours
prior to testing representing the
chronic condition, smokers were
tested again immediately after
smoking a cigarette of their usual
brand, representing the acute
condition

When comparing non-smokers
and chronic smokers , age
accounted for 29% of the overall
variance*; Na-PA amplitude was
larger in acute compared to
chronic smoking condition ***;
Wave V latency was longer in
older smokers compared to
younger smokers*; NS for
smoking behavior or interaction
of smoking behavior and age
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a

i

p

b

j

q

Questionnaire
Carbon Monoxide
c
Pure Tone Threshold
d
Acoustic Reflex Threshold
e
Auditory Brainstem Response
f
Transient Evoked Otoacoustic Emissions
g
Distortion Product Otoacoustic Emissions
h
Middle Latency Response

Auditory Evoked Potentials
Event Related Potentials
k
Global Initiative for Chronic Obstructive Lung
Disease
l
Chronic Obstructive Pulmonary Disease
m
Forced Expiratory Volume
n
Carboxyhemoglobin
o
Fagerstrom Test for Nicotine Dependence

Non-significant
Global Field Potential
r
Current Source Density
*p <0.05
**p <0.01
***p <0.001

DISCUSSION
The purpose of this systematic review was to determine the effects of smoking on
auditory function. Thus, studies examining a variety of outcome measures were included in the
present systematic review. Significant findings were present across all outcome measures,
including pure-tone thresholds, ultra high-frequency thresholds, OAEs, and AEPs, with the
majority of studies controlling for age and other confounding factors including noise exposure
and history of middle ear disorders.
Significantly worse thresholds were obtained in smokers compared to non-smokers in
both ears and across the conventional audiometric frequency range (.25 – 8k Hz) in the majority
of studies regardless of participant age (Chang et al., 2016; Fabry et al., 2011; Kumar et al.,
2013; Negley et al., 2007; Oliveira & Lima, 2009; Prabhu et al., 2017; Sekher et al., 2017). Of
note, a correlation was noted for those only exposed to secondhand smoke in the low – mid
frequency range (.5 – 2k Hz) (Fabry et al.). Significant differences in pure-tone thresholds were
also noted between those who never smoked and past smokers suggesting that the effects of
cigarette smoke on the auditory system are long-lasting, regardless of smoking cessation (Chang
et al.). Some discrepant findings were seen, however, as 3 studies did not obtain significant
findings in this frequency region (Gopal et al., 2009; Ohgami et al., 2011; Ramkissoon & Cole,
2011). Past smokers who had quit at least 3 years prior to testing were included in the nonsmoking group of one study in which results were non-significant (Ramkissoon & Cole). Perhaps
the long-lasting effects of smoking previously mentioned contaminated these findings resulting
in no significant differences between smokers and “non-smokers.” Gopal et al. only included
those with no history of hearing loss and examined a small sample size (16). Both of which may
contribute to their non-significant findings. Ohgami et al. also did not achieve a significant result
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in the conventional audiometric range, however, they did not examine the two lowest frequencies
(.25 - .5 Hz) typically included in this range.
The aforementioned effects of smoking generally observed on the conventional pure-tone
thresholds persisted in the ultra-high frequency range with both significantly worse thresholds in
smokers compared to non-smokers and a dose effect of decreasing thresholds with an increase in
smoke exposure (Ohgami et al., 2011; Oliveira & Lima, 2009; Paschoal & Azevedo, 2009;
Prabhu et al., 2017; Sumit et al., 2015). Effects in this frequency range, however, were more
frequency specific with the majority of significant findings obtained at 12 – 14k Hz (Ohgami et
al., 2011; Oliveira & Lima, 2009; Paschoal & Azevedo, 2009; Sumir et al., 2015). Two studies
noted these effects across the ultra-high frequency range (9 – 16k Hz, and 9 – 20k Hz) (Lisowska
et al., 2017; Prabhu et al.); in one of these two studies however, the findings trended towards
significance but failed to reach significance. Two studies did not find significant differences in
this range between smokers and non-smokers, however, they each had a small sample size
(Negley et al., 2007; Rogha et al., 2015).
Several subsets of OAEs were also measured and the results corroborate those noted for
both the conventional pure-tone thresholds and ultra high-frequency thresholds. Decreases in the
DPOAE and TEOAE amplitudes in the conventional frequency range were observed in smokers
in several studies (Gopal et al., 2009; Lisowska et al., 2017; Negley et al., 2007; Paschoal &
Azevedo, 2009; Prabhu et al., 2017; Rogha et al., 2015). In one study on DPOAEs in the ultra
high-frequency range (9 – 16k Hz), amplitudes were significantly lower in smokers than nonsmokers (Prabhu et al., 2017).
Significant effects of smoking were also found in AEP studies. Significant differences
occurred across latencies for ABR, auditory MLR, and long latencies potentials including P300
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(Gopal et al., 2009; Guney et al., 2009; Gupta et al., 2008; Jawinski et al., 2016; Mobascher et
al., 2009; Ramkissoon & Chambers, 2008). Both studies examining ABRs obtained significant
findings, however, one of which only noted a correlation between CO levels and wave V (Gopal
et al.). Gupta et al., on the other hand, found significant differences in several measures including
absolute latencies, interwave latencies, and amplitudes, but these effects were noted in
individuals with COPD, thus representing those most severely affected by smoke exposure.
Additionally, several findings in this study were ear-specific (Gupta et al.). While many studies
examining MLRs and smoking have been conducted, only one isolated the effects of cigarette
smoke and excluded those with psychological disgnoses. Significant findings, however, were
achieved (Ramkissoon & Chambers). In contrast to the negative correlations found, Ramkissoon
and Chambers observed a significantly larger Na-Pa amplitude in the acute than in the chronic
smoking condition. Those investigators speculated this finding illustrates the arousal effects of
nicotine that may be attributed to increase neural synchronization which presents as an excitatory
response, or in this study, larger Na-Pa responses.
In the remaining AEP studies, significant smoking effects were obtained on the long
latency potentials, specifically, N1-P2 and P300 (Guney et al., 2009; Jawinski et al., 2016;
Mobascher et al., 2009). Significantly lower N1-P2 amplitudes were noted in smokers compared
to non-smokers in the two studies which examined this measure (Guney et al.; Jawinski et al.).
One of these studies also noted significantly prolonged N1 latency in smokers when compared to
non-smokers. Similarly to N1-P2, of the two studies examining P300, both achieved significant
results. Specifically reduced P300 responses were noted in smokers compared to those who had
never smoked, and in one study, those categorized as light smokers (Mobascher et al.; Guney et
al.).
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A dose effect, illustrated in several different ways, was noted across outcome measures.
In regards to pure tone thresholds, the effect was noted in smokers in several studies with
thresholds increasing as smoke exposure, quantified as years smoking as well as packs per day,
increased (Kumar et al.; Prabhu et al.; Sumit et al., 2015). Similar to that of pure tone thresholds,
in one study, the amplitude of wave I in the right ear correlated negatively with duration of
illness, and the right ear, and amplitude of wave I in the left ear correlating negatively with packs
per years smoking (Gupta et al., 2008).
Supporting the idea of a dose effect, studies which examined either past smokers or those
exposed to SHS found significant differences between the aforementioned groups and those with
no smoke exposure at all, as well as significant differences between those groups and current
smokers. Significant differences in pure-tone thresholds were also noted between those who
never smoked and past smokers suggesting that the effects of cigarette smoke on the auditory
system are long-lasting, regardless of smoking cessation (Chang et al.). This effect was also
noted in studies examined AEPs as an outcome measure. Jawinski et al. found significantly
higher N1-P2 amplitudes in persons who never smoked followed by ex-smokers with the next
highest amplitude, and current smokers with the lowest N1-P2 amplitude. Although significant
differences between never smokers and current smokers, as well as never smokers and exsmokers were noted, no significant difference was noted between ex-smokers and current
smokers. Participants, however, in the ex-smoking group had quit smoking a minimum of 12
months prior to this study. Perhaps if ex-smokers had quit far longer prior to this study,
significant differences would have been achieved between these two groups. As mentioned
previously, despite smoking cessation, perhaps long term effects of smoking persist, thus
rendering differences in N1-P2 amplitude between ex- and current smokers non-significant.
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Supporting such, a significant dose effect was seen (N1-P2 amplitude inversely related to packs
per day and pack years) in ex- smokers (Jawinski et al., 2016). Effects were noted in P300
amplitude as well with persons who never smoked having significantly higher P300 GFP than
light smokers and similarly, persons who never smoked and light smokers had higher P300 GFP
than heavy smokers (Mobascher et al., 2009).
While a comparison can only be made in terms of conventional pure tone thresholds, as
the past review only included such, the present systematic review corroborates the
aforementioned meta-analysis, with positive correlations found in the majority of included
studies (Nomura, Nakao, and Morimoto, 2005). Furthermore, caution should be taken when
comparing the two reviews for several reasons. Nomura, Nakao, and Morimoto did not include
studies involving passive smokers and included those exposed to noise, in contrast to the present
review. Additionally, a vast majority of studies in the Nomura, Nakao and Morimoto review did
not adjust for age related differences. It should also be noted that subjects in studies published
after the meta-analysis, and those included in this review, were excluded if they had a history of
noise exposure whereas subjects with noise exposure histories were included in the studies
evaluated by Nomura, Nakao, and Morimoto. Statistical analyses, however, were performed to
adjust for noise exposure (Nomura, Nakao, & Morimoto).
The majority of studies (17 of 19) controlled for age in some capacity, whether it be only
including younger participants, delineating “younger” and “older” groups, statistically adjusting
for age, or age-matching control groups. Many, (15 of 19) however, did not adjust for gender nor
compare the results of male and female smokers and non-smokers. One study examining OAEs,
conventional pure tone thresholds, and ultra high frequency thresholds, found significant
differences between genders, with more significant effects occurring in male particpants, thus
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justifying the need for future research considering such (Lisowska et al., 2017). Very few studies
(3 of 19) included passive smokers and/or ex-smokers. As a dose effect was noted in several
studies across outcome measures when comparing passive smokers, ex-smokers, current
smokers, and non-smokers, future research delineating such groups is needed. Only 6 studies
utilized any form of auditory evoked potential, with 2 examining ABRs, 1 examining MLR and
the remaining 3 examining long latency potentials such as N1-P2 and/or P300. While significant
differences between smokers and non-smokers were achieved, future research is needed to
corroborate these findings. Additionally, one study examining ABRs obtained ear specific
significant differences between smokers and non-smokers (Gupta et al., 2008). Thus, future
research is needed to repeat the study with a larger sample size to see if these findings would
occur in both ears.
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CONCLUSION

The adverse effects of cigarette smoke on auditory function are present and clear
throughout the literature reviewed. As a result, smoking behavior should be avoided due to its
effects on auditory function, as well as the myriad of other heavily researched deleterious side
effects. Specific to the effects on auditory function, it would be advantageous to include a
question of smoking behavior in an audiologic evaluation intake form. This question should also
probe systematic exposure to secondhand smoke due to the effects of passive smoking.
Additionally, smoking cessation can be recommended to reduce effects on auditory function.
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